Cargando…
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/ https://www.ncbi.nlm.nih.gov/pubmed/35087243 http://dx.doi.org/10.1038/s41422-022-00617-x |
| _version_ | 1784640688099426304 |
|---|---|
| author | Xia, Shuai Chan, Jasper Fuk-Woo Wang, Lijue Jiao, Fanke Chik, Kenn Ka-Heng Chu, Hin Lan, Qiaoshuai Xu, Wei Wang, Qian Wang, Chao Yuen, Kwok-Yung Lu, Lu Jiang, Shibo |
| author_facet | Xia, Shuai Chan, Jasper Fuk-Woo Wang, Lijue Jiao, Fanke Chik, Kenn Ka-Heng Chu, Hin Lan, Qiaoshuai Xu, Wei Wang, Qian Wang, Chao Yuen, Kwok-Yung Lu, Lu Jiang, Shibo |
| author_sort | Xia, Shuai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8793821 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87938212022-01-28 Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant Xia, Shuai Chan, Jasper Fuk-Woo Wang, Lijue Jiao, Fanke Chik, Kenn Ka-Heng Chu, Hin Lan, Qiaoshuai Xu, Wei Wang, Qian Wang, Chao Yuen, Kwok-Yung Lu, Lu Jiang, Shibo Cell Res Letter to the Editor Springer Singapore 2022-01-27 2022-04 /pmc/articles/PMC8793821/ /pubmed/35087243 http://dx.doi.org/10.1038/s41422-022-00617-x Text en © The Author(s) under exclusive licence to Center for Excellence in Molecular Cell Science, CAS 2022 |
| spellingShingle | Letter to the Editor Xia, Shuai Chan, Jasper Fuk-Woo Wang, Lijue Jiao, Fanke Chik, Kenn Ka-Heng Chu, Hin Lan, Qiaoshuai Xu, Wei Wang, Qian Wang, Chao Yuen, Kwok-Yung Lu, Lu Jiang, Shibo Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title_full | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title_fullStr | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title_full_unstemmed | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title_short | Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant |
| title_sort | peptide-based pan-cov fusion inhibitors maintain high potency against sars-cov-2 omicron variant |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/ https://www.ncbi.nlm.nih.gov/pubmed/35087243 http://dx.doi.org/10.1038/s41422-022-00617-x |
| work_keys_str_mv | AT xiashuai peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT chanjasperfukwoo peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT wanglijue peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT jiaofanke peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT chikkennkaheng peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT chuhin peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT lanqiaoshuai peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT xuwei peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT wangqian peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT wangchao peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT yuenkwokyung peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT lulu peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant AT jiangshibo peptidebasedpancovfusioninhibitorsmaintainhighpotencyagainstsarscov2omicronvariant |